Regulus Therapeutics Inc. (NASDAQ:RGLS) was the target of a large increase in short interest in the month of October. As of October 30th, there was short interest totalling 932,300 shares, an increase of 12.9% from the October 15th total of 826,100 shares. Based on an average daily trading volume, of 520,400 shares, the short-interest ratio is presently 1.8 days.
RGLS has been the subject of several recent analyst reports. Zacks Investment Research lowered shares of Regulus Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, August 13th. HC Wainwright restated a “buy” rating on shares of Regulus Therapeutics in a research report on Tuesday, September 1st. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $1.08.
A hedge fund recently raised its stake in Regulus Therapeutics stock. Wedbush Securities Inc. lifted its position in Regulus Therapeutics Inc. (NASDAQ:RGLS) by 241.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 70,204 shares of the biopharmaceutical company’s stock after buying an additional 49,629 shares during the quarter. Wedbush Securities Inc. owned approximately 0.19% of Regulus Therapeutics worth $36,000 at the end of the most recent quarter. 17.64% of the stock is owned by institutional investors and hedge funds.
Regulus Therapeutics (NASDAQ:RGLS) last released its quarterly earnings data on Thursday, November 5th. The biopharmaceutical company reported ($0.04) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.21) by $0.17. Regulus Therapeutics had a negative net margin of 35,448.34% and a negative return on equity of 214.08%. On average, research analysts expect that Regulus Therapeutics will post -0.83 earnings per share for the current fiscal year.
About Regulus Therapeutics
Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States. Its two lead product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS4326, an anti-miR targeting miR-17, which is in Phase Ib clinical trial for the treatment of autosomal dominant polycystic kidney disease.
Further Reading: Bear Market – How and Why They Occur
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.